Fig. 2From: Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trialIOP (mmHg) changes at weeks 4,8 and 12. There was no significant change in mean IOP throughout the study periodBack to article page